CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
Queen Mary University of London
Londres, Reino UnidoPublications en collaboration avec des chercheurs de Queen Mary University of London (17)
2024
-
Making Information About Cladribine Tablets Accessible to People with Multiple Sclerosis: A Patient-Survey-Led Narrative Review for Healthcare Professionals
Neurology and Therapy, Vol. 13, Núm. 4, pp. 1015-1038
2023
-
A plain language summary of the impact of vaccines against flu and chickenpox in people with multiple sclerosis treated with cladribine tablets
Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 15-21
-
Development and usability testing of your MS questionnaire: A patient-based digital tool to monitor symptoms of multiple sclerosis
Digital Health, Vol. 9
-
European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176
-
Expert opinion on COVID-19 vaccines and cladribine tablets in MS: A plain language summary
Neurodegenerative Disease Management, Vol. 13, Núm. 1, pp. 5-13
-
Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: Systematic literature review of real-world evidence
Multiple Sclerosis and Related Disorders, Vol. 69
-
Summary of Research: Collaboration Between Healthcare Professionals and People with Multiple Sclerosis to Develop Communication Tools to Improve the Standard of Multiple Sclerosis Care
Advances in Therapy, Vol. 40, Núm. 12, pp. 5131-5136
2022
-
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846
-
Ocrelizumab during pregnancy and lactation: Rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants
Multiple Sclerosis and Related Disorders, Vol. 64
-
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456
-
Varicella zoster virus and influenza vaccine antibody titres in patients from MAGNIFY-MS who were treated with cladribine tablets for highly active relapsing multiple sclerosis
Multiple Sclerosis Journal
2021
-
Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice
Therapeutic Advances in Neurological Disorders, Vol. 14
-
Multiple sclerosis progression discussion tool usability and usefulness in clinical practice: Cross-sectional, web-based survey
Journal of Medical Internet Research, Vol. 23, Núm. 10
2019
-
Joint Healthcare Professional and Patient Development of Communication Tools to Improve the Standard of MS Care
Advances in Therapy, Vol. 36, Núm. 11, pp. 3238-3252
2018
-
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
The Lancet, Vol. 391, Núm. 10127, pp. 1263-1273
-
Unmet needs, burden of treatment, and patient engagement in multiple sclerosis: A combined perspective from the MS in the 21st Century Steering Group
Multiple Sclerosis and Related Disorders, Vol. 19, pp. 153-160
2015
-
Achieving patient engagement in multiple sclerosis: A perspective from the multiple sclerosis in the 21st Century Steering Group
Multiple Sclerosis and Related Disorders, Vol. 4, Núm. 3, pp. 202-218